Erevna is building an AI-native clinical trial management platform that lets community physicians run single-patient trial sites, attacking the bottleneck that keeps 97% of physicians and ~93% of eligible cancer patients out of research. The wedge is operational: by removing onboarding, compliance, budget negotiation, and patient-recruitment friction, Erevna makes it economic for a doctor to enroll even one patient — and that unlocks the long tail of community sites pharma sponsors increasingly need for label-expansion and rare-disease trials.
Validation is early but accelerating: meetings with 7 of the top 10 pharma companies, a signed CDA with a top-5 sponsor, two identified pilot trials (COPD and large-cell lung cancer), and a paid commercial wedge launched in Feb 2026 — an AI patient-referral-triage product live with a GI clinic at ~$6K ARR that cut time-to-triage 80%. Founders Daniel Fallon-Cyr (repeat founder, ex-Tilda PM) and Carl Schubert (ex-VTS engineering lead) have stopped taking salaries to extend runway. The deal has been on StoryHouse’s tracking list since Oct 2024; the team is currently raising a $1M pre-seed against a pivoted GTM and looking for SH feedback before re-engaging on terms.
Daniel emailed with a refined GTM after weeks of investor conversations: stop selling software directly to physicians; instead, give the platform to community clinics for free and use referral records as the entry point for clinical-trial patient identification, with pharma and medical-device companies as the economic buyer.
Mid-cycle update from Daniel: while big-pharma sales cycles drag (under CDA with two top-10 sponsors), the team built a community-clinic wedge by repurposing the CT platform tech into an AI patient-referral-triage product.
Update call covering progress since the $700K close, an expanded team and advisor bench, and the company’s shift toward Phase 3 label-expansion trials with big pharma in-house programs.